Venus Remedies Ltd
VENUSREMVenus Remedies Ltd
VENUSREM
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 19.20 | 0.87 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 420.28 | 402.31 | 374.66 | 327.98 | 375.99 | 600.36 | 608.49 | 565.83 | 613.03 | 633.08 | ||||||||||
Raw Materials | 242.04 | 223.58 | 204.84 | 189.67 | 168.45 | 347.94 | 383.50 | 322.95 | 357.35 | 567.00 | ||||||||||
| Power & Fuel Cost | 4.01 | 4.14 | 4.29 | 4.86 | 4.73 | 4.58 | 4.71 | 5.52 | 6.35 | |||||||||||
| Employee Cost | 32.44 | 34.27 | 39.31 | 42.10 | 46.02 | 46.02 | 52.33 | 57.05 | 66.95 | |||||||||||
| Selling & Administrative Expenses | 57.56 | 78.30 | 79.41 | 54.52 | 67.15 | 95.99 | 85.54 | 92.49 | 100.77 | |||||||||||
| Operating & Other expenses | 1.06 | 9.03 | 5.09 | 7.17 | 52.33 | 8.98 | 11.98 | 17.47 | 10.43 | |||||||||||
EBITDA | 83.17 | 52.99 | 41.72 | 29.66 | 37.31 | 96.85 | 70.43 | 70.35 | 71.18 | 66.08 | ||||||||||
| Depreciation/Amortization | 41.68 | 40.26 | 33.83 | 33.98 | 32.01 | 35.28 | 33.53 | 32.30 | 26.44 | 24.84 | ||||||||||
| PBIT | 41.49 | 12.73 | 7.89 | -4.32 | 5.30 | 61.57 | 36.90 | 38.05 | 44.74 | 41.24 | ||||||||||
| Interest & Other Items | 37.98 | 34.37 | 35.43 | 25.41 | 13.34 | 13.02 | 0.48 | 0.12 | 0.09 | 0.08 | ||||||||||
| PBT | 3.51 | -21.64 | -27.54 | -29.73 | -8.04 | 48.55 | 36.42 | 37.93 | 44.65 | 41.16 | ||||||||||
| Taxes & Other Items | 1.81 | -4.56 | 3.16 | -1.15 | 1.96 | -13.21 | -4.32 | 11.36 | 16.15 | 19.07 | ||||||||||
| Net Income | 1.70 | -17.08 | -30.70 | -28.58 | -10.00 | 61.76 | 40.74 | 26.57 | 28.50 | 22.09 | ||||||||||
| EPS | 1.49 | -14.36 | -24.87 | -23.16 | -8.10 | 50.04 | 31.69 | 19.88 | 21.32 | 16.53 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Venus Remedies Ltd | 14.88 | 0.87 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare VENUSREM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
VENUSREM has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2013
Dividend/Share
₹3.00
Ex DateEx Date
Sep 23, 2013
Cash Dividend
Ex DateEx DateSep 20, 2012
Dividend/Share
₹3.00
Ex DateEx Date
Sep 20, 2012
Cash Dividend
Ex DateEx DateSep 22, 2011
Dividend/Share
₹3.00
Ex DateEx Date
Sep 22, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Dividend/Share
₹3.00
Ex DateEx Date
Sep 23, 2010
Net profit of Venus Remedies declined 64.69% to Rs 3.51 crore in the quarter ended September 2024 as against Rs 9.94 crore during the previous quarter ended September 2023. Sales declined 0.16% to Rs 167.45 crore in the quarter ended September 2024 as against Rs 167.72 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales167.45167.72 0 OPM %2.9410.61 - PBDT15.4820.78 -26 PBT9.0714.34 -37 NP3.519.94 -65 Powered by Capital Market - Live
Venus Remedies will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live
Venus Remedies announced that the 35th Annual General Meeting (AGM) of the company will be held on 23 September 2024.Powered by Capital Market - Live
Net profit of Venus Remedies rose 3.39% to Rs 1.22 crore in the quarter ended June 2024 as against Rs 1.18 crore during the previous quarter ended June 2023. Sales rose 14.15% to Rs 108.61 crore in the quarter ended June 2024 as against Rs 95.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales108.6195.15 14 OPM %10.3710.93 - PBDT12.8312.60 2 PBT6.855.05 36 NP1.221.18 3 Powered by Capital Market - Live
Venus Remedies will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Venus Remedies has postponed the meeting of the Board of Directors which was scheduled to be held on 20 July 2024. The meeting will now be held on a later date.Powered by Capital Market - Live
Venus Remedies edges higher after bagging supply order for oncology drugs from PAHO
Venus Remedies up 8% on order win from UNICEF for bacterial infection drug
Venus Remedies soars after bagging Ceftriaxone supply contract from UNICEF
Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 13.33%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.15% to 0.16%